Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913

Introduction In preclinical data, the combination therapy with S-1 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) had a synergistic antitumor effect on non-small cell lung cancer (NSCLC), regardless of the EGFR mutation status. Patients and Methods Patients with previous...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakahara, Yoshiro, Shimokawa, Tsuneo, Misumi, Yuki, Nogami, Naoyuki, Shinkai, Tetsu, Seki, Nobuhiko, Hosomi, Yukio, Hida, Naoya, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851018/
https://www.ncbi.nlm.nih.gov/pubmed/32803700
http://dx.doi.org/10.1007/s10637-020-00985-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851018/
https://www.ncbi.nlm.nih.gov/pubmed/32803700
http://dx.doi.org/10.1007/s10637-020-00985-4

Ejemplares similares